Understanding how a protein called TIRR affects p53, a key player in cancer
Elucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53
This work aims to uncover how a protein named TIRR influences p53, a critical protein that helps protect our bodies from cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11130999 on NIH RePORTER |
What this research studies
Our cells have a natural defense system against cancer, and a protein called p53 is a major part of it, often called the 'guardian of the genome.' Another protein, 53BP1, helps p53 do its job, especially in repairing damaged DNA and stopping abnormal cell growth. However, we don't fully understand how 53BP1 and p53 work together. This project focuses on a newly identified protein, TIRR, which appears to control how 53BP1 interacts with p53. By learning more about this interaction, we hope to better understand how cells prevent cancer.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit individuals with various cancers by advancing our understanding of disease mechanisms.
Not a fit: Patients seeking immediate treatment options may not directly benefit from this basic science research, as it focuses on fundamental biological processes.
Why it matters
Potential benefit: If successful, this work could reveal new targets for developing future cancer treatments by better understanding how cells regulate tumor suppression.
How similar studies have performed: While the role of 53BP1 in DNA repair is well-known, the specific interaction between TIRR, 53BP1, and p53 is a novel area with limited prior understanding.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Chowdhury, Dipanjan — Dana-Farber Cancer Inst
- Study coordinator: Chowdhury, Dipanjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.